Oncology

Merck KGaA
Biotech

Merck KGaA taps BenevolentAI, Exscientia for AI drug discovery

The three-target deals are collectively worth more than $30 million upfront and $1 billion in potential milestones.
Nick Paul Taylor Sep 20, 2023 6:00am
handshake deal shake hand arrows ok yes

Singapore's HiRO snaps up US oncology CRO Courante

Sep 6, 2023 3:05pm
mergers acquisitions

Verastem bags options on GenFleet RAS programs to grow pipeline

Aug 28, 2023 10:30am
picnic lunch snack basket hat fruit food

PicnicHealth enters the oncology field with AstraZeneca collab

Aug 23, 2023 4:30am
timer sand clocks time

Aravive, weeks from liquidation, lays off 70% of its staff

Aug 22, 2023 8:50am
cell therapy oncology cancer CAR-T cells

Letter of the day for Alphabet's Verily is O for OneOncology

Aug 17, 2023 4:30am
More News

Gilead, Tentarix ink $66M oncology, inflammatory disease deal

Aug 15, 2023 10:22am

Moderna plots lung cancer trial for Merck-partnered vaccine

Aug 2, 2023 3:28pm

Roche inks KSQ deal to expand stable of synthetic lethal assets

Jul 13, 2023 9:20am

Leal Health adds FDA-approved cancer treatment decision support

Jun 22, 2023 4:30am